Immunocore (IMCR) Short Interest Ratio & Short Volume → Trump’s Former Wingman Bets Big on AI (From Banyan Hill Publishing) (Ad) Free IMCR Stock Alerts $55.85 -1.14 (-2.00%) (As of 05/14/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Immunocore Short Interest DataCurrent Short Volume4,570,000 sharesPrevious Short Volume4,090,000 sharesChange Vs. Previous Month+11.74%Dollar Volume Sold Short$270.00 millionShort Interest Ratio / Days to Cover11.2Last Record DateApril 30, 2024Outstanding Shares49,820,000 sharesFloat Size48,780,000 sharesShort Percent of Float9.37%Today's Trading Volume227,394 sharesAverage Trading Volume446,162 sharesToday's Volume Vs. Average51% Short Selling Immunocore ? Sign up to receive the latest short interest report for Immunocore and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatIMCR Short Interest Over TimeIMCR Days to Cover Over TimeIMCR Percentage of Float Shorted Over Time Ad Porter & CompanyTruth about Trump you’ve never heardEverything about Donald Trump is public. Every part of his life has been dragged out in the media. But there’s one story I bet you’ve never heard about Trump. For the full story, click here. Immunocore Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20244,570,000 shares $270.00 million +11.7%9.4%11.2 $59.08 4/15/20244,090,000 shares $227.16 million -11.3%8.4%8.2 $55.54 3/31/20244,610,000 shares $299.65 million +7.5%9.5%9.4 $65.00 3/15/20244,290,000 shares $260.96 million +1.4%8.8%8.9 $60.83 2/29/20244,230,000 shares $284.34 million +9.6%8.7%8.6 $67.22 2/15/20243,860,000 shares $272.13 million +20.6%8.0%8.2 $70.50 Get the Latest News and Ratings for IMCR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter. 1/31/20243,200,000 shares $231.33 million +8.1%6.6%6.7 $72.29 1/15/20242,960,000 shares $211.82 million +2.4%6.1%8 $71.56 12/31/20232,890,000 shares $197.44 million -13.0%6.0%8.4 $68.32 12/15/20233,320,000 shares $213.04 million -17.2%6.9%10.1 $64.17 11/30/20234,010,000 shares $211.45 million -3.4%8.3%13.1 $52.73 11/15/20234,150,000 shares $198.95 million +12.5%8.6%15.4 $47.94 10/31/20233,690,000 shares $163.84 million +7.3%8.0%14.2 $44.40 10/15/20233,440,000 shares $172.65 million +4.6%7.4%15 $50.19 9/30/20233,290,000 shares $170.75 million +3.8%7.1%14.9 $51.90 9/15/20233,170,000 shares $167.34 million +6.0%6.9%15.1 $52.79 8/31/20232,990,000 shares $168.25 million +4.2%6.2%15.2 $56.27 8/15/20232,870,000 shares $172.92 million +8.3%6.0%14.2 $60.25 7/31/20232,650,000 shares $174.85 million -4.7%5.8%12.8 $65.98 7/15/20232,780,000 shares $176.25 million No Change6.1%12 $63.40 6/30/20232,780,000 shares $166.69 million -4.1%6.1%11.5 $59.96 6/15/20232,900,000 shares $168.03 million +7.8%6.4%11.3 $57.94 5/31/20232,690,000 shares $148.43 million -5.0%5.7%10.2 $55.18 5/15/20232,830,000 shares $174.44 million +14.6%6.0%10.8 $61.64 4/30/20232,470,000 shares $143.38 million -1.6%5.3%9.5 $58.05 4/15/20232,510,000 shares $137.57 million +0.4%5.3%9.7 $54.81 3/31/20232,500,000 shares $123.60 million +8.7%5.3%9.5 $49.44 3/15/20232,300,000 shares $121.12 million +10.1%4.9%8.6 $52.66 2/28/20232,090,000 shares $114.64 million No Change4.5%6.9 $54.85 2/15/20232,090,000 shares $134.87 million No Change4.5%6.3 $64.53 1/31/20232,090,000 shares $128.05 million +8.9%4.5%5.8 $61.27 1/15/20231,920,000 shares $122.00 million +39.1%4.1%4.9 $63.54 12/30/20221,380,000 shares $78.76 million -28.5%3.0%3.6 $57.07 12/15/20221,930,000 shares $114.68 million +27.0%4.1%5.2 $59.42 11/30/20221,520,000 shares $95.47 million -9.5%3.3%3.9 $62.81 11/15/20221,680,000 shares $109.33 million -15.6%3.6%4.4 $65.08 10/31/20221,990,000 shares $113.71 million -13.9%5.2%6 $57.14 10/15/20222,310,000 shares $111.76 million +6.9%6.1%7.8 $48.38 9/30/20222,160,000 shares $101.39 million +27.8%5.7%7.7 $46.94 9/15/20221,690,000 shares $76.17 million +89.5%4.4%5.7 $45.07Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (Ad)The AI boom continues to snowball with no signs of slowing... Google CEO, Sundar Pichai, made waves during a recent call with analysts, reminding them that the search engine company has been “AI first” since 2016.Get the full story here. IMCR Short Interest - Frequently Asked Questions What is Immunocore's current short interest? Short interest is the volume of Immunocore shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 4,570,000 shares of IMCR short. 9.37% of Immunocore's shares are currently sold short. Learn More on Immunocore's current short interest. What is a good short interest ratio for Immunocore? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IMCR shares currently have a short interest ratio of 11.0. Learn More on Immunocore's short interest ratio. What is a good short interest percentage for Immunocore? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 9.37% of Immunocore's floating shares are currently sold short. Is Immunocore's short interest increasing or decreasing? Immunocore saw a increase in short interest in April. As of April 30th, there was short interest totaling 4,570,000 shares, an increase of 11.7% from the previous total of 4,090,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Immunocore's float size? Immunocore currently has issued a total of 49,820,000 shares. Some of Immunocore's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Immunocore currently has a public float of 48,780,000 shares. How does Immunocore's short interest compare to its competitors? 9.37% of Immunocore's shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Immunocore: Twist Bioscience Co. (20.49%), Denali Therapeutics Inc. (8.16%), Arcellx, Inc. (8.89%), Iovance Biotherapeutics, Inc. (22.64%), SpringWorks Therapeutics, Inc. (13.51%), Vericel Co. (9.22%), Recursion Pharmaceuticals, Inc. (24.98%), Apogee Therapeutics, Inc. (14.00%), Kymera Therapeutics, Inc. (16.15%), ADMA Biologics, Inc. (3.82%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Immunocore stock? Short selling IMCR is an investing strategy that aims to generate trading profit from Immunocore as its price is falling. IMCR shares are trading down $1.14 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Immunocore? A short squeeze for Immunocore occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IMCR, which in turn drives the price of the stock up even further. How often is Immunocore's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMCR, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Twist Bioscience Short Squeeze Denali Therapeutics Short Squeeze Arcellx Short Squeeze Iovance Biotherapeutics Short Squeeze SpringWorks Therapeutics Short Squeeze Vericel Short Squeeze Recursion Pharmaceuticals Short Squeeze Apogee Therapeutics Short Squeeze Kymera Therapeutics Short Squeeze ADMA Biologics Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IMCR) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityBuy this small stock before coming AI Tidal WaveChaikin AnalyticsRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperElon’s New Device is About to Shock the WorldInvestorPlace